Bernhard Witzenbichler

Bernhard Witzenbichler

Auto-generated profile, based on publicly available information

Bernhard Witzenbichler

Helios Amper-Klinikum , Dachau 85221, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2008 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GSGregg W. Stone
Gregg W. Stone
BWBernhard Witzenbichler
Bernhard Witzenbichler
GGGiulio Guagliumi
Giulio Guagliumi
JPJan Z. Peruga
Jan Z. Peruga
BBBruce R. Brodie
Bruce R. Brodie
RMRoxana Mehran
Roxana Mehran
Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina and non−ST-segment elevation acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI). The safety and efficacy of bivalirudin in high-risk patients are unknown. We randomly assigned 3602 patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI to treatment with heparin plus a glycoprotein IIb/IIIa inhibitor or to treatment with bivalirudin alone. The two primary end points of the study were major bleeding and combined adverse clinical events, defined as the combination of major bleeding or major adverse cardiovascular events, including death, reinfarction, target-vessel revascularization for ischemia, and stroke (hereinafter referred to as net adverse clinical events) within 30 days. Anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in a reduced 30-day rate of net adverse clinical events (9.2% vs. 12.1%; relative risk, 0.76; 95% confidence interval [CI] 0.63 to 0.92; P=0.005), owing to a lower rate of major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 95% CI, 0.46 to 0.77; P<0.001). There was an increased risk of acute stent thrombosis within 24 hours in the bivalirudin group, but no significant increase was present by 30 days. Treatment with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in significantly lower 30-day rates of death from cardiac causes (1.8% vs. 2.9%; relative risk, 0.62; 95% CI, 0.40 to 0.95; P=0.03) and death from all causes (2.1% vs. 3.1%; relative risk, 0.66; 95% CI, 0.44 to 1.00; P=0.047). In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, NCT00433966.)

1 August 2013 in The Lancet
Verified
Journal Article
Closed access
GSGregg W Stone
Gregg W Stone
BWBernhard Witzenbichler
Bernhard Witzenbichler
GWGiora Weisz
Giora Weisz
MRMichael J Rinaldi
Michael J Rinaldi
FNFranz-Josef Neumann
Franz-Josef Neumann
TSThomas D Stuckey
Thomas D Stuckey

1 November 2013 in The Lancet
Verified
Journal Article
Closed access
RMRoxana Mehran
Roxana Mehran
UBUsman Baber
Usman Baber
GSGabriel Steg
Gabriel Steg
CACono Ariti
Cono Ariti
GWGiora Weisz
Giora Weisz
SPStuart Pocock
Stuart Pocock

2 May 2012 in JAMA
Verified
Journal Article
Open access
PDF file
GSGregg W. Stone
Gregg W. Stone
AMAkiko Maehara
Akiko Maehara
BWBernhard Witzenbichler
Bernhard Witzenbichler
JGJacek Godlewski
Jacek Godlewski
HPHelen Parise
Helen Parise
CGC. Michael Gibson
C. Michael Gibson
Primary percutaneous coronary intervention (PCI) is widely accepted as the most effective reperfusion modality for ST-segment elevation myocardial infarction (STEMI). However, myocardial recovery after primary PCI is often suboptimal despite restoration of coronary blood flow, in part due to thrombus embolization resulting in impaired microvascular perfusion.1-4 Two strategies proposed to reduce distal embolization after primary PCI are bolus infusion of intracoronary abciximab5-8 and manual thrombus aspiration.9-13

7 May 2009 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GSGregg W. Stone
Gregg W. Stone
ALAlexandra J. Lansky
Alexandra J. Lansky
SPStuart J. Pocock
Stuart J. Pocock
BGBernard J. Gersh
Bernard J. Gersh
GDGeorge Dangas
George Dangas
RMRoxana Mehran
Roxana Mehran
There is no consensus regarding the safety and efficacy of drug-eluting stents, as compared with bare-metal stents, in patients with ST-segment elevation myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI). We randomly assigned, in a 3:1 ratio, 3006 patients presenting with ST-segment elevation myocardial infarction to receive paclitaxel-eluting stents (2257 patients) or otherwise identical bare-metal stents (749 patients). The two primary end points of the study were the 12-month rates of target-lesion revascularization for ischemia (analysis powered for superiority) and a composite safety outcome measure of death, reinfarction, stroke, or stent thrombosis (powered for noninferiority with a 3.0% margin). The major secondary end point was angiographic evidence of restenosis at 13 months. Patients who received paclitaxel-eluting stents, as compared with those who received bare-metal stents, had significantly lower 12-month rates of ischemia-driven target-lesion revascularization (4.5% vs. 7.5%; hazard ratio, 0.59; 95% confidence interval [CI], 0.43 to 0.83; P=0.002) and target-vessel revascularization (5.8% vs. 8.7%; hazard ratio, 0.65; 95% CI, 0.48 to 0.89; P=0.006), with noninferior rates of the composite safety end point (8.1% vs. 8.0%; hazard ratio, 1.02; 95% CI, 0.76 to 1.36; absolute difference, 0.1 percentage point; 95% CI, −2.1 to 2.4; P=0.01 for noninferiority; P=0.92 for superiority). Patients treated with paclitaxel-eluting stents and those treated with bare-metal stents had similar 12-month rates of death (3.5% and 3.5%, respectively; P=0.98) and stent thrombosis (3.2% and 3.4%, respectively; P=0.77). The 13-month rate of binary restenosis was significantly lower with paclitaxel-eluting stents than with bare-metal stents (10.0% vs. 22.9%; hazard ratio, 0.44; 95% CI, 0.33 to 0.57; P<0.001). In patients with ST-segment elevation myocardial infarction who were undergoing primary PCI, implantation of paclitaxel-eluting stents, as compared with bare-metal stents, significantly reduced angiographic evidence of restenosis and recurrent ischemia necessitating repeat revascularization procedures. No safety concerns were apparent at 1 year. (ClinicalTrials.gov number, NCT00433966.)

1 June 2011 in The Lancet
Verified
Journal Article
Closed access
GSGregg W Stone
Gregg W Stone
BWBernhard Witzenbichler
Bernhard Witzenbichler
GGGiulio Guagliumi
Giulio Guagliumi
JPJan Z Peruga
Jan Z Peruga
BBBruce R Brodie
Bruce R Brodie
RMRoxana Mehran
Roxana Mehran